OncoSenX uses a unique lipid nanoparticle and plasmid DNA to target solid tumors based on transcriptional activity, inducing apoptosis in cancerous cells. Their approach is less invasive and more precise than traditional cancer treatments, providing hope for cancer patients, doctors, and medical care professionals. OncoSenX is headquartered in Seattle, Washington and is a late stage pre-clinical cancer company.